COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel corona-virus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
FRENOVO FLU A+B & COIVD-19 antigen rapid test qualitatively detects the presence of Influenza A and/or Influenza B antigen in nasal swab or throat swab or nasal aspirate specimens, providing results within 15 minutes.
COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel corona-virus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
FRENOVO FLU A+B & COIVD-19 antigen rapid test qualitatively detects the presence of Influenza A and/or Influenza B antigen in nasal swab or throat swab or nasal aspirate specimens, providing results within 15 minutes.
COVID-19 Ag Rapid Test is designed to detect antigen from the SARS-CoV-2 in human nasopharyngeal swab specimens from patients who are suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. The Celltrion DiaTrustTM COVID-19 Ag Rapid Test is validated for use from direct specimens testing without transport media.
An external positive control is needed to confirm that the device performs as intended and that the test procedure is conducted correctly. 0.1 μg/mL of non-infectious recombinant SARS-CoV-2 RBD antigen and 0.1 μg/mL non-infectious recombinant SARS-CoV-2 nucleoprotein antigen is dried onto the swab. This control swab should be tested once with every new lot and shipment, on a daily basis, for each new user, or according to the quality control procedures established for each laboratory.
English
